Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).
The intense marketing of unproven stem cell interventions has become an international health concern. The authors offer resources and suggestions for physicians seeking to effectively counsel patients and respond to their questions about various stem cell therapies.
The authors examine a proposal for new human embryo and embryoid guidelines, writing that before conducting any research beyond day 14, scientists must develop clear, thoughtful and culturally sensitive guidelines that include limitations and oversight procedures to ensure that science responds to societal needs and values.
Kirstin R.W. Matthews, Ana S. Iltis, Sam LoweDecember 21, 2021
The recent shift toward legalization has not been enough to undo the racism endemic to U.S. cannabis policy. The authors lay out policies to improve equity and erase the racist legacy of prohibition.
Katharine Neill Harris, William MartinOctober 1, 2021
This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.
Kirstin R.W. Matthews, Ana S. Iltis, Sarah HooverSeptember 22, 2021
Hospital at Home programs offer an alternative care model for acutely ill patients to receive intensive at-home treatment. With better policy and operations, can this model work at scale in the United States beyond the pandemic?
Anaeze C. Offodile II, Celynne Balatbat, Kushal T. Kadakia, Victor DzauAugust 23, 2021
Although Texans broadly support relaxing cannabis laws and other criminal justice reforms, state leaders continue the war on drugs and other policies that propagate systemic racism, writes fellow Katharine Neill Harris.
The unproven stem cell intervention industry is a worldwide, direct-to-consumer market where clinics offer stem cells or stem cell-derived components to patients with little to no scientific or clinical basis. In this paper, the authors call for the establishment of a World Health Organization Expert Advisory Committee on Regenerative Medicine to tackle this issue and provide guidance. Stem Cell Reports: https://doi.org/10.1016/j.stemcr.2021.05.004
The authors sought to develop and test a tool that accurately predicts the unique financial burden to individual patients undergoing treatment for breast cancer. JCO Clinical Cancer Informatics, an American Society of Clinical Oncology Journal
Anaeze C. Offodile II, Chris Sidey-Gibbons, André Pfob, Malke Assad, Stefanos Boukovalas, Yu-Li Lin, Jesse Creed Selber, Charles ButlerMarch 26, 2021